

Annual Flash Report (unaudited)

Fiscal Year ended March 31, 2017

Consolidated Statement of Cash Flows

Ono Pharmaceutical Co., Ltd. and Consolidated Subsidiaries

	Millions of yen		Thousands of US\$
	Year ended March 31, 2016	Year ended March 31, 2017	Year ended March 31, 2017
Cash flows from operating activities			
Profit before tax	¥ 33,272	¥ 74,540	\$ 665,536
Depreciation and amortization	6,534	7,821	69,829
Impairment losses	1,188	937	8,368
Interest and dividend income	(2,782)	(2,951)	(26,349)
Interest expense	13	15	132
(Increase) Decrease in inventories	2,562	(2,042)	(18,231)
(Increase) Decrease in trade and other receivables	(20,099)	(11,195)	(99,960)
Increase (Decrease) in trade and other payables	9,312	4,980	44,463
Increase (Decrease) in provisions	613	4,731	42,240
Increase (Decrease) in retirement benefit liabilities	(6,031)	389	3,477
Increase (Decrease) in long-term advances received	(909)	(538)	(4,806)
Other	(3,722)	6,292	56,176
Subtotal	19,951	82,978	740,876
Interest received	314	154	1,373
Dividends received	2,522	2,818	25,163
Interest paid	(13)	(15)	(132)
Income taxes paid	(9,932)	(11,485)	(102,548)
Net cash provided by (used in) operating activities	12,842	74,450	664,731
Cash flows from investing activities			
Purchases of property, plant, and equipment	(7,021)	(14,805)	(132,187)
Proceeds from sales of property, plant and equipment	936	274	2,449
Purchases of intangible assets	(7,061)	(9,274)	(82,805)
Purchases of investments	(863)	(3,240)	(28,933)
Proceeds from sales and redemption of investments	27,693	28,883	257,880
Payments into time deposits	(800)	(20,800)	(185,714)
Other	153	974	8,693
Net cash provided by (used in) investing activities	13,037	(17,989)	(160,616)
Cash flows from financing activities			
Dividends paid to owners of the parent company	(19,059)	(20,116)	(179,606)
Dividends paid to non-controlling interests	(3)	(3)	(31)
Repayments of long-term borrowings	(366)	(398)	(3,558)
Net increase (decrease) in short-term borrowings	11	(11)	(102)
Purchases of treasury shares	(49)	(22)	(199)
Net cash provided by (used in) financing activities	(19,465)	(20,552)	(183,496)
Net increase (decrease) in cash and cash equivalents	6,414	35,909	320,619
Cash and cash equivalents at the beginning of the period	104,222	110,485	986,471
Effects of exchange rate changes on cash and cash equivalents	(152)	(71)	(630)
Cash and cash equivalents at the end of the period	¥ 110,485	¥ 146,323	\$ 1,306,460